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Abstract
Background: HIV+ patients on highly active antiretroviral therapy (HAART) with suppressed viral loads have a low
incidence of HIV-associated dementia, but increased prevalence of milder forms of HIV-associated neurocognitive
disorders (HAND). These milder forms of HAND are often associated with minimal histological abnormalities, and
their pathophysiology is unclear. Comorbidities, altered amyloid metabolism, accelerated brain aging, and activated
interferon responses are suspected to play a role in HAND pathogenesis in HAART–treated persons.
Methods: To investigate associations between liver disease, accelerated brain aging, and HAND in HIV+ patients in
the late HAART era (2002–2015), we studied liver and brain autopsy tissues from 53 older subjects evaluated at
UCLA and BWH using histopathological stains, a sensitive fluorescent amyloid stain (AmyloGlo), and targeted gene
expression profiling (NanoString).
Results: The majority of HIV+ subjects (median age 56) were on HAART (89.3%) with last pre-mortem plasma viral
load <400 copies/mL (81.5%); 50% had CD4+ counts <200 cells/μL. Compared to HIV- controls (median age 65), HIV+
subjects had more cancer (p = 0.04), illicit drug use (p <0.00001), and HCV co-infection (p = 0.002), less cardiovascular
disease (p = 0.03), and similar prevalence of cerebrovascular disease (~40%), hypertension, hyperlipidemia, and diabetes.
Deep frontal white matter showed increased gliosis in HIV+ subjects vs. HIV- controls (p = 0.09), but no significant
differences in myelin loss, blood vessel thickening, or inflammation. Liver showed more severe fibrosis/cirrhosis
(p = 0.02) and less steatosis (p = 0.03) in HIV+ subjects, but no significant differences in inflammation, blood vessel
thickness, or pigment deposition. There were no significant associations between liver and brain pathologies.
AmyloGlo staining detected large amyloid deposits in only one HIV+ case (age 69 with Alzheimer’s disease
pathology) and two HIV- controls (ages 66 and 74). White matter from HIV+ cases vs. HIV- seronegative controls
showed a trend (p = 0.06) towards increased interferon response gene expression (ISG15, MX1, IFIT1, IFIT2, and IFITM1).
(Continued on next page)
* Correspondence: dana_gabuzda@dfci.harvard.edu
2Department of Cancer Immunology and Virology, Dana-Farber Cancer
Institute, Boston, USA
4Department of Neurology, Harvard Medical School, Boston, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Solomon et al. BMC Infectious Diseases  (2017) 17:151 
DOI 10.1186/s12879-017-2246-7
(Continued from previous page)
Conclusions: Gliosis and cerebrovascular disease, but not accelerated amyloid deposition, are common brain
pathologies among older HIV+ patients in the late HAART era. Although HIV+ subjects had more cirrhosis, liver
pathology was not associated with any consistent pattern of brain pathology. Cerebrovascular disease, interferon
responses, and neuroinflammation are likely factors contributing to brain aging and HAND in older HIV+ patients on
current HAART regimens.
Keywords: HIV, HIV-associated neurocognitive disorders, Alzheimer’s disease, Amyloid, Neuropathology, Liver, White
matter, Inflammation, Interferon response
Background
HIV-associated dementia (HAD), the most severe form
of HIV-associated neurocognitive disorders (HAND),
affected approximately 20% of AIDS patients prior to
death in the pre-highly active antiretroviral therapy
(HAART) and early HAART eras (1981–2001) [1, 2].
In the pre-HAART era, HAD pathogenesis was
largely attributed to viral replication in brain macro-
phages/microglia, immune activation in the CNS, and
neuronal loss, due to the effects of neurotoxic viral
proteins and pro-inflammatory cytokines. This model
was consistent with the classic neuropathologic find-
ings in HIV encephalitis (HIVE), characterized by
multinucleated giant cells, diffuse microgliosis, micro-
glial nodules, neuronal loss, astrocyte hypertrophy,
myelin pallor, and immunoreactivity for HIV antigens
including p24 [3, 4]. In the late HAART era (2002–
present), milder forms of HAND, such as minor neu-
rocognitive disorder (MND) and asymptomatic neuro-
cognitive impairment (ANI), are more prevalent, with
estimates ranging from 20 to 50% of HAART-treated
HIV+ individuals depending upon the sample studied
[2, 5, 6]. Brains from these individuals often show
minimal or non-specific histopathologic changes re-
gardless of their pre-mortem cognitive status [7, 8].
Consequently, the pathophysiology of these milder
forms of HAND is poorly understood. As the HIV+
population ages, it is becoming increasingly important
to distinguish HAND from other forms of dementia
that are common in the general population, such as
Alzheimer’s disease (AD).
A variety of mechanisms have been proposed to ex-
plain HAND pathogenesis in the late HAART era. HIV
enters the brain early after acute infection, with macro-
phages and microglia serving as the major reservoirs of
replicating and latent virus. Effective HAART suppresses
viral replication but does not affect latent virus, even in
maximally treated persons [9]. Interruption of HAART
leads to dramatic elevation in peripheral, brain, and CSF
viral loads, increasing the risk of serious CNS conse-
quences [10, 11]. In persons on continuous HAART,
brief, low-level episodes of viral escape or “blipping” in
brain and CSF may contribute to HAND by inducing
immune activation and inflammation [12] and dysregula-
tion of the tryptophan-kynurenine pathway, resulting in
accumulation of neurotoxic metabolites [13]. The neuro-
vascular unit, consisting of CNS blood vessels and their
interface with brain parenchyma, may also be involved
in HAND pathogenesis [4]. The neurovascular unit is in-
volved in maintenance of the blood–brain barrier and
regulation of microvascular blood flow, so chronic or
intermittent disturbance of its components may lead to
irreversible damage. Some antiretroviral drugs have been
associated with neurotoxic effects, which may also con-
tribute to or exacerbate HAND [14]. Brain function is
also influenced by overall health and co-morbidities, in-
cluding those affecting liver function, such as HCV in-
fection and alcohol use. Therefore, liver disease and
other comorbidities are additional factors that could po-
tentially contribute to some forms of HAND [15, 16].
Lastly, some investigators have proposed that HIV infec-
tion and/or HAART may cause neurocognitive impair-
ment by disrupting amyloid metabolism [17].
To elucidate mechanisms contributing to HAND
pathogenesis in the late HAART era, we examined asso-
ciations between liver pathology, brain aging, and
HAND in studies of brain and liver autopsy tissue from
older HIV+ patients on HAART compared to controls
during the calendar period 2002–2015 by histopatho-
logical methods, a sensitive fluorescent amyloid staining
method (AmyloGlo), and targeted gene expression pro-
filing (NanoString).
Methods
Cohort selection and characterization
A cohort of older HIV+ patients (defined as > =age 45 at
death) and age-matched controls with available autopsy
brain frontal lobe and liver tissue was assembled from
the National Neurological AIDS Bank (NNAB) at UCLA
[18] and Pathology Specimen Locator Core at Brigham
and Women’s Hospital (BWH). All subjects were en-
rolled with written informed consent and Institutional
Review Board (IRB) approval at each study site. Aut-
opsy tissue samples, demographic, clinical, and labora-
tory data were collected and coded to protect
participants' confidentiality in accordance with IRB-
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approved protocols at UCLA, BWH, and DFCI. To
identify older HIV- controls, we searched for persons
aged 45–80 years with no history of HIV. To identify
older HIV+ cases, we searched for participants aged
45–80 on HAART for at least 1 year, including the year
prior to death, with a recorded last pre-mortem plasma
viral load (VL) within 12 months prior to death of
<1000 copies/mL or undetectable (<50 or 400 copies/
ml, depending upon the year that the test was ob-
tained). Efforts were made to exclude cases with fatal
stroke, CNS hemorrhage, Parkinson’s Disease, multiple
sclerosis, active CNS opportunistic infection, neuro-
syphilis and brain tumor. The following cases not meet-
ing all search or exclusion criteria were included: four
cases under age 45 (range, 33–41 years), four cases with
last plasma VL >1000 copies/mL (range, 1985–70,953
copies/ml), four cases that stopped HAART in the last
few months prior to death, one with hemorrhagic middle
cerebral artery stroke, and three with active fungal or bac-
terial infections involving the CNS at time of death.
Pathologic evaluation
Formalin-fixed brain frontal lobe and liver tissues
were obtained for cases from NNAB. Representative
tissue was processed and paraffin-embedded using
standard histological protocols by the Specialized
Histopathology Services Longwood Core at BWH.
Unstained formalin-fixed paraffin-embedded (FFPE)
tissue sections were prepared from NNAB and BWH
cases. All frontal lobe sections were stained with
hematoxylin and eosin (H&E) and luxol fast blue and
periodic acid-Schiff (LFB-PAS). Selected cases were
also examined by glial fibrillary acidic protein (GFAP)
(ab7260, Abcam, Cambridge, UK) and amyloid-beta
(Aβ) (M0872, Dako, Glostrup, Denmark) immunohis-
tochemistry. Liver sections were stained with H&E
and Masson’s trichrome. All slides were reviewed by
two study pathologists.
AmyloGlo and immunofluorescence staining
FFPE frontal lobe tissue sections were stained with Amy-
loGlo RTD (Biosensis, Thebarton, Australia) according
to the manufacturer’s protocol in phosphate buffered sa-
line for 10 min [19]. Slides were then stained with
mouse anti-CD68 monoclonal antibody (M0876, Dako)
and rabbit anti-GFAP polyclonal antibody followed by
goat anti-mouse AlexaFluor 488 (A-11001 l, Invitrogen,
Waltham, MA) and goat anti-rabbit AlexaFluor 647
(A-21245, Invitrogen). Incubation with Sudan Black B
(Sigma Aldrich, St. Louis, MO) (1.0% in 70% ethanol)
for 10 min was done prior to cover-slipping. Slides
were imaged with a Leica SP8 X Confocal Microscope
and images analyzed with Fiji [20] and Adobe Photo-
shop software.
Gene expression profiling
Subcortical white matter mRNA was extracted from
FFPE tissue sections (13 BWH cases), or frozen frontal
lobe sections (5 NNAB cases) using a FFPE DNA/RNA
isolation kit according to the manufacturer's instructions
(Qiagen, Valencia, CA). RNA content and quality (RIN;
RNA integrity number) were evaluated using BioAnaly-
zer (Agilent). mRNA hybridization, detection, and scan-
ning were performed using NanoString nCounter
technology and software (NanoString Technologies,
Seattle, WA) [21] at the DFCI Molecular Biology core
facility. For FFPE samples, RNA input was adjusted to
100 ng based on the percentage of RNA greater than
50–300 bp to normalize for RNA degradation in FFPE
tissue samples. Each RNA sample was probed with a
custom probe set to detect mRNA transcripts for 24
cellular genes including 11 cell type-specific markers
(neuronal, oligodendrocyte, astrocyte, macrophage/
microglial, endothelial cells) and 13 inflammation/im-
mune activation markers (see Additional file 1). Eight
additional probes to detect housekeeping gene tran-
scripts were used for normalization. Quality control
checks and data normalization using internal negative
and positive controls and housekeeping genes was
performed using nSolver 3.0 software. From 18 cases
with RNA isolated from 13 FFPE and five frozen tis-
sue samples, four cases with high expression of neur-
onal markers (i.e. SNAP25 and SYN1) were excluded
from the final analysis, resulting in 14 cases available
for analysis of gene expression.
Statistics
Statistical significance was determined by Student’s t-test
or Chi-squared test (p-values <0.05). For analysis of gene
expression using NanoString technology, fold- change
and p-values were calculated using Student's t-test (p <
0.05), false discovery rate (FDR) was calculated using
fdrtool in R (FDR < 0.10), and semi-supervised heatmaps
were generated using R.
Results
Cohort characteristics
Nineteen HIV+ and nine HIV- subjects from UCLA
were combined with 9 HIV+ and 16 HIV- subjects from
BWH, for a total of 28 HIV+ and 25 HIV- subjects ex-
amined at autopsy during the late HAART era (2002–
2015). Demographic, clinical characteristics, and labora-
tory data, and differences between the two groups, are
summarized in Table 1. The median age of the HIV+
group was approximately 10 years younger compared to
the HIV- control group (p = 0.001), and included more
males (p = 0.006), while race showed no significant dif-
ferences between groups. The median post-mortem
interval for HIV- controls was longer compared to HIV+
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Table 1 Demographics, clinical characteristics, and laboratory data of the study cohort
HIV-positive (n = 28) HIV-negative (n = 25) p-value
Demographics
Age at death (years) 56.1 (8.9) 64.9 (15.1) 0.001
Gender (male) 23 (82.0) 11 (44.0) 0.006
Race (Caucasian) 23 (42.9) 13 (52.0) 0.5
Post-mortem interval (hours) 13.5 (16.4) 24 (40.5) 0.03
Substance use and comorbidities
Smoking 16 (57.1) 10 (40.0) 0.2
Illicit drugs 18 (64.3) 0 (0.0) <0.00001
Alcohol 11 (39.3) 0 (0.0) 0.0004
HCV or HBV infection 15 (46.0) 2 (8.0) 0.002
BMI 22.9 ± 3.8 26.8 ± 6.0 0.05
Hypertension 17 (60.7) 16 (64.0) 0.8
Diabetes 4 (14.3) 5 (20.0) 0.6
Hyperlipidemia 19 (67.9) 17 (68.0) 0.99
Cancer 13 (46.4) 5 (20.0) 0.04
Cardiovascular disease 12 (42.9) 18 (72.0) 0.03
Cerebrovascular disease 12 (42.9) 10 (40.0) 0.99
HAND 9 (32.1) - -
Laboratory values
Creatinine (mg/dL) 2.1 ± 1.7 1.9 ± 1.2 0.7
ALT (U/L) 57.8 ± 63.3 70.5 ± 122.1 0.7
AST (U/L) 80.5 ± 112.0 108.5 ± 140.1 0.5
ALP (U/L) 131.2 ± 201.0 98.1 ± 47.2 0.2
Total bilirubin (mg/dL) 4.4 ± 9.8 1.8 + 4.4 0.3
Total cholesterol (mg/dL) 183.9 ± 79.8 185.5 ± 44.9 0.9
LDL (mg/dL) 78.9 ± 30.5 107.2 ± 43.3 0.09
HDL (mg/dL) 40.3 ± 16.6 49.7 ± 16.1 0.2
Triglycerides (mg/dL) 172.7 ± 62.3 170.6 ± 86.8 0.9
HgA1c (%) 5.1 ± 0.7 6.3 ± 1.6 0.04
APOE genotype (E4) 3 (14.3) ND -
HIV-related characteristics
CD4 count (cells/μL) 214.7 ± 161.1 - -
CD4 count <200 cells/μL 14 (50.0)
Plasma viral load (copies/mL) 295 (1307) - -
Plasma viral load <400 copies/mL 22 (81.5)
CSF viral load <40 copies/mL 7 (87.5) - -
On HAART 25 (89.3) - -
AIDS-related causes of death 10 (35.7) - -
Values represent n (%), mean ± STDEV, or median (IQR). p-values from Student’s t-test or Chi-squared test
Abbreviations: HCV hepatitis C virus, HBV hepatitis B virus, BMI body mass index, HAND HIV-associated neurocognitive disorders, ALT alanine transaminase, AST as-
partate transaminase, LDL low-density lipoprotein, HDL high-density lipoprotein, HgA1c hemoglobin A1C, APOE apolipoprotein E, CSF cerebrospinal fluid; HAART,
highly-active antiretroviral therapy, ND not done. Cerebrovascular disease is based on medical records and autopsy findings. HAND diagnoses include: four asymp-
tomatic neurocognitive impairment (ANI), two minor neurocognitive disorder (MND), and three HIV-associated dementia (HAD). Laboratory values are the last re-
corded pre-mortem values within 12 months prior to death
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cases (p = 0.03), reflecting the NNAB’s rapid autopsy
protocol. HIV+ cases were more likely to be positive for
HCV or HBV (p = 0.002) and to report use of illicit
drugs (mainly cocaine and other stimulants) (p <0.0001)
or alcohol (p = 0.0004). There were no significant differ-
ences in BMI, or prevalence of smoking, hypertension,
diabetes, hyperlipidemia, or cerebrovascular disease,
while cardiovascular disease was slightly more prevalent
(p = 0.03), and BMI and HgA1c values were higher, in
HIV- compared to HIV+ subjects (p = 0.04). Cancer was
more prevalent in HIV+ cases than controls (p = 0.04)
and included diagnoses of primary CNS lymphoma,
Kaposi sarcoma, squamous cell carcinoma of the tongue,
and squamous cell carcinoma of the anus. There were
no significant differences in laboratory values related to
kidney and liver function or cholesterol homeostasis.
Apolipoprotein E (APOE) genotypes were available only
for HIV+ cases, of which 3/21 (14.3%) had at least one
ε4 allele. Eighty-nine % of HIV+ cases were on HAART,
50% had a last recorded CD4+ count <200 cells/μL
(mean 214.7 +/− 161.1), 81.5% had a last recorded
plasma VL <400 copies/mL, and 7/8 (87.5%) had un-
detectable CSF VL (one case had CSF VL 942 copies/
mL at time of death). Nine of 28 (32.1%) HIV+ cases
had a HAND diagnosis (4 ANI, 2 MND, and 3 HAD)
and ten died of AIDS-related causes (e.g., opportunistic
fungal infections, Pneumocystis jirovecii pneumonia,
non-Hodgkin’s lymphoma, Kaposi’s sarcoma).
Brain histopathologic features
In autopsy reports, the most common brain pathologies
were infarcts/ischemia (45.3%), hemorrhage/hematoma
(9.4%), large vessel atherosclerosis (7.5%), arterial/arteri-
olar sclerosis (11.3%), and evidence of current or prior
infection (e.g. cryptococcal meningitis, aspergillus)
(17.0%). FFPE brain frontal lobe tissue, including grey
matter and subcortical white matter, was available for
evaluation in 27 HIV+ and 22 HIV- cases, the results of
which are summarized in Table 2. A minority of HIV+
and HIV- cases (11.1% and 9.1%, respectively) were
histopathologically unremarkable (Fig. 1a, e). Many HIV
+ and HIV- cases exhibited mild histopathologic abnor-
malities including hypercellular white matter (Fig. 1b, f ),
increased rod cells (microglia) (Fig. 1c, g), moderately
thickened blood vessels (highlighted by PAS stain)
(Fig. 1d, h), or myelin loss (demonstrated by LFB stain),
but there were no statistically significant differences be-
tween the groups. Grey matter exhibited minimal gliosis
(Fig. 2a-b, e-f ), while the majority of HIV+ and HIV-
cases demonstrated diffuse white matter gliosis by GFAP
immunohistochemistry, and a minority of cases exhib-
ited focal perivascular gliosis (Fig. 2c-d, g-h). A non-
Table 2 Brain frontal lobe histopathologic features
Histologic feature Assessment HIV-positive (n = 27)a HIV-negative (n = 22)a p-value
n (%) n (%)
Astrocytes Normal 16 (59.3) 18 (81.8) 0.09
(H&E) Increased 11 (40.7) 4 (18.2)
Activated astrocytes Diffuse white matter 17 (100) 15 (93.8) 0.3
(GFAP IHC) White matter vessels 3 (17.6) 1 (6.25) 0.3
Grey matter 4 (23.5) 3 (18.8) 0.7
Microglia Normal 9 (33.3) 7 (31.8) 0.9
Increased 18 (66.7) 15 (68.2)
Myelin Normal 15 (55.6) 13 (59.1) 0.8
Loss 12 (44.4) 9 (40.9)
Blood vessel thickening None 19 (70.4) 13 (59.1) 0.6
Mild 4 (14.8) 3 (13.6)
Moderate/severe 4 (14.8) 6 (27.3)
Inflammation None 19 (70.4) 17 (77.3) 0.5
Chronic 5 (18.5) 3 (13.6)
Acute 0 (0.0) 1 (4.5)
Amyloid deposition
(AmyloGlo) positive 1 (5.9) 2 (12.5) 0.5
Values listed represent n (%). p-values from Chi-squared test
Abbreviations: GFAP glial fibrillary acidic protein, IHC immunohistochemistry
aFor GFAP IHC and AmyloGlo, N = 17 for HIV+ and N = 16 for HIV-
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statistically significant trend (p = 0.09) suggested a
greater proportion of cases with gliosis in the HIV+
group compared to controls. Inflammation was present
in a minority of cases including five HIV+ cases with
chronic inflammatory infiltrates compared to three
controls with chronic and one control with acute inflam-
matory infiltrates. Brain histopathologic features listed in
Table 2 showed no significant associations with HAND
(all p-values > 0.10, chi-squared test; n = 9 with HAND
vs. n = 18 without HAND).
Fig. 1 Brain frontal lobe histopathologic findings in HIV+ cases and controls. Representative formalin-fixed paraffin embedded autopsy brain
frontal lobe tissue from HIV- (a-d) and HIV+ (e-h) cases stained with hematoxylin and eosin (a-c, e-g) or luxol fast blue and periodic acid-Schiff
(d, h). A minority of HIV+ and HIV- cases were histologically unremarkable (a, e). Many HIV+ and HIV- cases exhibited mild histopathologic abnormalities
including hypercellular white matter (b, f), increased rod cells (microglia) (c, g), and/or moderately thickened blood vessels (d, h). Original magnification
200× (a-b, e-f), 400× (d, h), and 1000× (c, g)
Fig. 2 Grey and white matter gliosis in HIV+ cases compared to controls. Representative formalin-fixed paraffin embedded autopsy brain frontal
lobe tissue from HIV- (a-d) and HIV+ (e-h) cases stained with hematoxylin and eosin (a, c, e, g) or glial fibrillary acidic protein (GFAP) immunohis-
tochemistry. Grey matter exhibited minimal gliosis (a, b, e, f), while the majority of HIV+ and HIV- cases demonstrated diffuse white matter gliosis,
and a minority of cases exhibited focal perivascular gliosis (c, d, g, h). Original magnification 400×
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Amyloid deposition in brain
Staining for amyloid deposits with the fluorescent com-
pound AmyloGlo was performed on FFPE frontal lobe
sections for 17 HIV+ and 16 HIV- cases, with GFAP and
CD68 immunofluorescent co-staining. Large amyloid pla-
ques with dense central cores were identified in only one
HIV+ (69-year-old female with Alzheimer’s disease histo-
pathology at autopsy) and two HIV- cases (66 year old
male and 74 year old female) (Fig. 3a-b, d-f). All three
cases had GFAP-positive astrocytes adjacent to amyloid
plaques, and rare CD68-positive microglia. Morphology of
the amyloid plaques was similar to the positive control
case (Braak Stage V-VI Alzheimer’s disease), as demon-
strated by Aβ immunohistochemistry (Fig. 3c, f, i).
Liver histopathologic findings
In autopsy reports, the most common liver pathologies
were micro- or macro-steatosis (26.4%), severe fibrosis/
cirrhosis (24.5%), inflammatory infiltrates (24.5%), necro-
sis (13.2%), and primary or metastatic carcinoma (9.4%).
FFPE liver was available for evaluation in 24 HIV+ and
18 HIV- cases, with results summarized in Table 3. A
minority of HIV+ and HIV- cases (16.7% and 16.7%, re-
spectively) were histologically unremarkable (Fig. 4a, e).
Moderate to severe micro-and macrovesicular steatosis
was more common in controls (66.7%) than in HIV+
cases (41.6%, p = 0.03) (Fig. 4b, f ), while severe fibrosis/
cirrhosis was more common in HIV+ cases (58.3%) than
in controls (33.3%, p = 0.02) (Fig. 4d, h). Cases with mild
or moderate to severe inflammation and necrosis were
identified in both HIV+ and control groups without sig-
nificant differences in prevalence between groups. Bile
duct proliferation (p = 0.03) and lipofuscin (p = 0.04) but
not bile pigment deposition were more prevalent in HIV
+ cases than controls. In 39 cases with available paired
liver and brain sections, there were no significant associ-
ations between moderate to severe liver pathology and
brain pathologies listed in Table 2 (all p-values ≥ 0.10;
n = 14 no/mild liver pathology vs. n = 25 moderate/se-
vere liver pathology, chi-squared test of groups stratified
by HIV status). We also found no significant associations
between moderate to severe liver pathology and HAND
Fig. 3 Fluorescent staining of brain amyloid in HIV+ cases and controls. Representative formalin-fixed paraffin embedded autopsy brain frontal
lobe tissue from HIV- (a-c) and HIV+ (d-f) cases and a known Alzheimer’s disease (AD) case (g-i) were examined by AmyloGlo staining
(blue) (a-b, d-e, g-h), CD68 (green) and GFAP (red) immunofluorescence (b, e, h), or amyloid-beta (Aβ) immunohistochemistry (c, f, i).
Large amyloid plaques with dense central cores were identified in one HIV+ and two HIV- cases, with peripheral GFAP-positive astrocytes
and rare CD68-positive microglia. The plaques were confirmed to contain Aβ protein, and exhibited similar morphology to the positive
control (AD) case. Original magnification 400×
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(p = 0.11, chi-squared test; n = 9 with HAND vs. n = 18
without HAND).
Gene-expression profiles
Subcortical white matter from 6 HIV+ and 12 HIV-
cases was isolated and mRNA extracted for gene expres-
sion profiling using the NanoString nCounter platform
to detect a targeted panel of 24 genes, consisting of
genes involved in interferon responses and inflamma-
tion, and cell-type specific markers of macrophages/
microglia, astrocytes, oligodendrocytes, neurons, and
endothelial cells. After excluding four samples with high
expression of neuronal gene transcripts (i.e. SNAP25
and SYN1), indicating significant contamination with
Table 3 Liver histopathologic features
Histologic feature Assessment HIV-positive (n = 24) HIV-negative (n = 18) p-value
n (%) n (%)
Fibrosis (grade) 1 3 (12.5) 9 (50.0) 0.02
2 7 (29.2) 3 (16.7)
3 3 (12.5) 4 (22.2)
4 - cirrhosis 11 (45.8) 2 (11.1)
Inflammation None 9 (37.5) 6 (33.3) 0.6
Mild 6 (25.0) 7 (38.9)
Moderate/severe 6 (25.0) 4 (22.2)
Necrosis 3 (12.5) 1 (5.6)
Steatosis None 10 (41.7) 4 (22.2) 0.03
Focal 4 (16.7) 2 (11.1)
Moderate 2 (8.3) 9 (50.0)
Severe 8 (33.3) 3 (16.7)
Bile duct proliferation Present 10 (41.7) 2 (11.1) 0.03
Pigments Bile 11 (45.8) 3 (16.7) 0.05
Lipofuscin 7 (29.2) 11 (61.1) 0.04
Values listed represent n (%). p-values from Chi-squared test
Fig. 4 Liver histopathologic findings in HIV+ cases and controls. Representative formalin-fixed paraffin embedded autopsy liver tissue from HIV-
(a-d) and HIV+ (e-h) cases stained with hematoxylin and eosin (a-b, e-f) or Masson’s trichrome stain (c-d, g-h). A minority of HIV+ and HIV- cases
were histologically unremarkable (a, c, e, g), while several HIV+ and HIV- cases exhibited moderate to severe micro- and macrovesicular steatosis
(b, f) and/or severe fibrosis/cirrhosis (d, h). Original magnification 40× (c-d, g-h) or 400× (a-b, e-f)
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grey matter, six HIV+ and eight HIV- cases were avail-
able for analysis. After normalization of values using
eight housekeeping genes to control for variability in
quantity and quality of input RNA, 24 cellular genes
were examined for differences in mRNA transcript levels
between HIV+ cases vs. controls (see Additional file 1).
A set of five genes involved in interferon (IFN) responses,
MX1, ISG15, IFIT1, IFIT2, and IFITM1, showed a trend
towards higher expression of mRNA transcripts in HIV+
cases compared to controls (p = 0.06; Fig. 5 and Additional
file 1). This difference was largely driven by two HIV+
cases with high levels of IFN-response gene transcripts
(BWH HIV+ 1 and UCLA HIV+ 25 with autopsy diagno-
ses of sepsis with endocarditis and microemboli in brain
and other tissues, and with Alzheimer’s disease, respect-
ively); the remaining four HIV+ cases had minimal to
moderate elevations in IFN-induced gene transcripts com-
pared to controls. To exclude the possibility that differ-
ences in RNA quality accounted for differences in levels of
IFN response gene transcripts, we examined RIN values,
which ranged from 2.1 to 4.7 (mean 2.6 +/−0.73); these
low values were expected given that RNA was isolated
from autopsy FFPE tissues. RIN values showed no associ-
ation with differences in levels of IFN-response mRNA
transcripts, indicating that differences in levels of IFN-
response gene expression were not attributable to differ-
ences in the quantity or quality of input RNA.
Discussion
This is the first comparative study of brain and liver
histopathology in older HIV+ patients on ART with low
or undetectable VL in the late HAART era. As expected,
classic findings of HIVE, such as multinucleated giant
cells and microglial nodules, were not observed. Instead,
we observed nonspecific histologic findings commonly
seen in autopsy brain from HIV+ patients in the late
HAART era, such as mild histopathologic abnormalities,
anoxic-ischemic changes, focal parenchymal and sub-
arachnoid hemorrhage, Alzheimer type II astrocytes (in-
dicative of hepatic encephalopathy), and primary CNS or
systemic lymphoma [7, 22, 23]. Contrary to expectations,
frontal lobe pathology of HIV+ and HIV- cases was sur-
prisingly similar, and showed no significant associations
with liver pathology or HAND. Deep white matter from
HIV+ cases showed increased gliosis compared to HIV-
controls, but no differences in myelin loss, blood vessel
thickening, or inflammation. With regard to liver path-
ology, severe fibrosis/cirrhosis was more common in
HIV+ cases, largely attributable to HCV or HBV co-
infection, while moderate to severe steatosis was more
common in controls and frequency of liver inflammation
and necrosis was similar between groups. HIV+ subjects
were reasonably well matched to controls for many clin-
ical characteristics including smoking and vascular risk
factors, with exception of the younger median age (56
vs. 65 years in HIV+ and HIV-, respectively). Moreover,
the results we report remained similar using data from
HIV+ vs. HIV- groups more closely matched for me-
dian age (n = 24 HIV+ vs. n = 20 HIV-; median age 57
vs. 62 years, p = 0.133) or from the HIV+ cases with
controlled VL (<400 HIV RNA copies/mL) and no evi-
dence of active infections near time of death (n = 21
HIV+ vs. n = 25 HIV-).
Accelerated aging has been proposed to occur in HIV
patients and contribute to mechanisms underlying
HAND among older HIV+ individuals [6, 24, 25].
Fig. 5 Expression of interferon-response genes in frontal lobe subcortical white matter from HIV+ cases compared to controls. Semi-supervised
heatmap showing increased expression and hierarchical clustering of interferon-response genes in white matter from HIV+ cases compared to
controls. One hundred nanograms of RNA from HIV+ and HIV- cases was probed to detect mRNA transcripts using the NanoString nCounter plat-
form (see Additional file 1). Red and blue boxes indicate HIV+ and HIV- cases, respectively
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Previous studies reported that levels of Aβ deposited in
brain correlate with brain HIV viral loads [23]. However,
other studies found no correlation between cognitive
deficits and Aβ levels [26, 27], so there is lack of consen-
sus regarding Aβ deposits in HAND. To assess the bur-
den of Aβ deposits in frontal lobe, we used AmyloGlo, a
fluorescent amyloid stain with advantages over alterna-
tive compounds due to its excitability in the UV range,
and suitability for multiple immunofluorescence labeling
[19]. Large, predominantly cortical amyloid deposits
with dense cores were detected in only one HIV+ pa-
tient, a 69-year-old black female with unsuppressed CSF
VL (942 copies/mL) and AD pathology at time of aut-
opsy; amyloid plaques were surrounded by GFAP-
positive reactive astrocytes and scattered CD68-positive
microglia. No definitive clinical diagnosis of HAND or
AD was made for this subject, who had additional co-
morbidities prior to death, including cocaine use, myo-
cardial infarction, and metastatic gastric carcinoma. Two
control cases (ages 66 and 74 years) without clinical
diagnoses of AD also had Aβ deposition in brain de-
tected by Amyloglo. Although several studies reported
Aβ plaques in HIV+ individuals with predominance of
diffuse plaques or intraneuronal deposits [28–30], we
detected no morphologic differences between HIV+ and
HIV- Aβ deposits. Some studies reported increased rates
of HAND with Aβ plaques among APO ε4 carriers,
while others reported no increased risk [30–33]. In our
study, no amyloid plaques were identified in two HIV+
cases with APO ε4 genotype, and the HIV+ case with
amyloid plaques was an APO ε3 homozygote. Published
reports of HIV+ patients with cognitive features of AD
are rare, in part due to difficulties distinguishing AD
from HAND and other comorbidities [34, 35]. Taken to-
gether, these findings argue against accelerated amyloid
deposition among HIV+ individuals.
Cerebrovascular disease causes significant morbidity in
the HIV+ population, where increased prevalence in
younger individuals has been associated with viral repli-
cation and inflammation, as well as dyslipidemia and
pro-atherogenic effects of some ART drugs [6, 36]. HIV
infection is an independent risk factor for stroke, and
untreated cerebrovascular risk factors, including hyper-
tension and hyperlipidemia, have detrimental effects on
neurocognition [37–40]. Chronic inflammation associ-
ated with HIV infection has been implicated in promot-
ing atherosclerosis, and an increase in brain large artery
inflammation was recently demonstrated in HIV+ pa-
tients [41]. Compared to several prior studies, HIV+
subjects in our cohort were of similar age or slightly
older, with higher prevalence of cerebrovascular risk fac-
tors including smoking, illicit drug use, hypertension,
hyperlipidemia, and diabetes. Some of these cohort dif-
ferences may reflect the population recruited by NNAB,
which preferentially recruits individuals with severe ill-
ness likely to result in mortality, compared to other co-
horts. In contrast to many prior studies, cardiovascular
disease was more prevalent and HgA1c was higher in
the HIV- group in our study cohort compared to con-
trols. The HIV- group in our study was ~10 years older
than the HIV+ group, raising the possibility that the lack
of a significant difference in prevalence of cerebrovascu-
lar disease between groups may also reflect the younger
age of the HIV+ subjects. Supporting this hypothesis,
the ages of HIV+ cases with moderate to severe cerebro-
vascular pathology ranged from 39 to 68 years (median
58), while the ages of HIV- controls with similar path-
ology ranged from 54 to 77 years (median 73).
Liver disease including chronic viral hepatitis, drug-
associated hepatotoxicity, non-alcoholic fatty-liver dis-
ease, and opportunistic infections accounts for signifi-
cant morbidity and mortality in the HIV+ population
[42, 43]. Failure of the liver to remove toxins from the
blood causes hepatic encephalopathy via mechanisms in-
volving increased ammonia and inflammation, and is
histologically associated with the presence of Alzheimer
type II astrocytes in brain [44]. HIV co-infection with
HCV or HBV occurs frequently, due to shared routes of
transmission, often progressing to cirrhosis. In some
studies, liver fibrosis has been associated with adverse ef-
fects on cognitive performance in HIV/HCV co-infected
individuals [45]. The liver plays a central role in choles-
terol metabolism and clotting, which can have profound
systemic and CNS effects [46]. Previous histopathologic
studies reported frequent fatty changes, inflammation,
cirrhosis, bile stasis, and carcinoma in livers of HIV+ pa-
tients at autopsy [22, 47]. Similar findings were identified
in the present study, including, fibrosis/cirrhosis, steato-
sis, inflammation, and pigment deposition. Severe fibro-
sis/cirrhosis was more common in HIV+ individuals
than controls, which can be attributed to significantly
higher rates of HCV co-infection and alcohol consump-
tion. Micro- and macrosteatosis were more common in
the HIV- subjects, and there was no significant differ-
ence in inflammation, blood vessel thickness, or pigment
deposition. Alzheimer type II astrocytes were observed
in frontal subcortical white matter in three HIV+ cases,
all with HCV co-infection. Despite the frequency of
these findings, no consistent histologic patterns were
identified in frontal lobe or liver from HIV+ patients
and we found no significant associations between liver
and brain pathologies.
To elucidate molecular mechanisms contributing to
HAND, gene expression profiling was performed on
frontal subcortical white matter using the NanoString
nCounter platform with a targeted panel of cell-type spe-
cific and inflammatory markers. To our knowledge, this is
the first study to utilize NanoString technology to study
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HIV neuropathogenesis in FFPE tissue. NanoString is a
useful technology for the study of FFPE tissues, which are
generally more available than frozen tissue. A significant
advantage is the ability to obtain quantitative signals from
low RNA concentrations, or partially degraded RNA, due
to signal detection by short probes that do not require an
amplification step. Customization of the probe set allowed
for inclusion of neuronal markers, which we used to iden-
tify and exclude samples with significant grey matter con-
tamination from the final analysis of white matter
samples. Prior studies using the Affymetrix array platform
examined gene expression in white matter from HIV+ in-
dividuals with and without inflammation and cognitive
deficits [48–50]. These studies demonstrated elevated ex-
pression of IFN-response genes in patients with HIVE and
modest elevations in expression of these genes in HIV-
infected patients without HIVE or neurocognitive impair-
ment. Consistent with these studies, we detected a trend
towards increased expression of the IFN-response genes
MX1, ISG15, IFIT1, IFIT2, and IFITM1 in HIV+ cases
compared to controls. RIN values were low, as expected
for FFPE tissue, but showed no association with IFN-
response transcript levels, arguing against low RNA qual-
ity or longer PMI as the explanation for differences in
gene expression levels. Two HIV+ cases had particularly
high expression of these genes, both black females (ages
58 and 69) with histories of illicit drug use, last CD4 cell
counts < 300 cells/μL, on HAART with last plasma VL <
400 copies/mL: one had endocarditis and sepsis with
microemboli in multiple organs including brain, while the
other had Alzheimer’s disease pathology and positive
AmyloGlo staining. Given these comorbidities, increased
IFN-response gene expression in these two cases was not
clearly attributable to HAND. The remaining four HIV+
cases had only minimal to moderate elevations of IFN-
induced gene expression compared to controls. Histologic
evidence of chronic inflammation was present in 2/6
(33%) HIV+ cases (including the 58-year-old female with
endocarditis) compared to 1/8 (12.5%) HIV- cases. Inflam-
matory infiltrates and IFN-responses in brain are often lo-
calized in a patchy distribution, and might be detected in
more cases if additional areas were sampled. While these
gene expression data have limitations and show only a
trend toward statistical significance, they are in agreement
with previous studies [48, 50–52]. Thus, IFN-induced
gene expression may represent a core signature indicative
of ongoing immune activation mediated through IFN re-
sponse pathways even in HIV+ individuals with sup-
pressed VL on ART in the late HAART era.
While this study has many strengths, there were several
limitations including inherent bias related to selection of
autopsy subjects, quality of post-mortem tissues available,
and availability of clinical and laboratory data. The major-
ity of HIV+ cases were from the NNAB at UCLA, which
preferentially recruits HIV+ individuals at risk of death
who agree to contribute their tissues for research, in-
creases the likelihood of identifying subjects with neuro-
cognitive deficits. Conversely, the majority of HIV- cases
came from routine hospital autopsies at BWH, which in-
cludes many patients suffering from chronic diseases, car-
diovascular disease, prolonged care in the intensive care
unit, and/or unexplained causes of death. BWH cases had
longer PMIs than NNAB cases, as NNAB stresses rapid
autopsy whenever possible. However, tissue from BWH
was more rapidly processed and paraffin-embedded than
tissue from NNAB. Prolonged formalin-fixation precluded
recovery of usable mRNA for gene expression studies
from NNAB cases, requiring analysis of RNA isolated
from frozen tissue available for a subset of cases. Clinical
and laboratory data was not complete for all patients, in-
cluding lack of formal evaluation for HAND in BWH HIV
+ cases, likely underestimating some co-morbidities.
Lastly, the sample size was relatively small, which limited
statistical power for some analyses, particularly for gene
expression profiling. Larger, prospective studies with fo-
cused data collection from HIV+ subjects with controlled
VL and no other active infections near time of death are
needed to avoid these issues in future studies and gain
new insights into pathological mechanisms in successfully
treated patients.
Conclusions
This study is the first to compare paired brain and liver
histopathology in older HIV+ individuals with sup-
pressed viral loads in the late HAART era with HIV
seronegative controls. Several lines of evidence suggest
connections between liver function and brain pathology
in the general population due to the role of the liver in
detoxifying blood, cholesterol metabolism, and clotting,
and modulation of systemic inflammation and vascular
disease. Although significant histopathologic findings
were identified in both frontal lobe and liver specimens,
no consistent patterns or inter-relationships between
liver and frontal lobe histopathology were identified in
HIV+ individuals. AmyloGlo was used for the first time
in this setting, and may prove useful for future studies of
Alzheimer’s disease and brain aging in HIV+ individuals.
Gene expression profiling using NanoString revealed a
trend towards increased IFN response genes, in agree-
ment with prior studies, implicating chronic inflamma-
tion as one of several possible factors contributing to the
development of neurocognitive deficits in this popula-
tion. Examination of a larger number of samples with a
broader panel of targets as well as new molecular path-
ology tools are needed to elucidate mechanisms under-
lying mild forms of HAND in the era of newer HAART
regimens, and define the relationship of HAND to co-
morbidities involving other organ systems.
Solomon et al. BMC Infectious Diseases  (2017) 17:151 Page 11 of 13
Additional file
Additional file 1: Gene expression profiling of frontal lobe subcortical
white matter. Table listing 24 genes profiled using the Nanostring
nCounter platform to quantify mRNA transcripts. (DOCX 13 kb)
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